Skip to main content
Terug
MAZE logo

Maze Therapeutics, Inc.

Datakwaliteit: 100%
MAZE
NASDAQ Healthcare Biotechnology
€ 49,00
▲ € 0,97 (2,02%)
Marktkapitalisatie: 2,36B
Dagbereik
€ 47,00 € 49,18
52-Weeksbereik
€ 6,71 € 53,65
Volume
512.668
50D / 200D Gem.
€ 45,69 / € 29,72
Vorige Slotkoers
€ 48,03

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E 45,1 0,4
P/B 12,0 2,9
ROE % 50,5 3,8
Net Margin % 31,2 3,9
Rev Growth 5Y % 10,0
D/E 0,1 0,2

Belangrijkste Punten

ROE of 50,47% indicates high profitability
Net margin of 31,18% shows strong profitability
Debt/Equity of 0,14 — conservative balance sheet
Generating 74,81M in free cash flow
P/E of 45,14 — premium valuation
Cash machine — converts 143,22% of earnings into free cash flow

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
50,47%
ROIC19,32%
Net Margin31,18%
Op. Margin34,38%

Veiligheid

Debt / Equity
0,14
Current Ratio9,76
Interest Coverage0,00

Waardering

P/E Ratio
45,14
P/B Ratio11,97
EV/EBITDA37,99
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 167,50M Net Income (TTM) 52,23M
ROE 50,47% ROA 21,71%
Gross Margin 100,00% Operating Margin 34,38%
Net Margin 31,18% Free Cash Flow (TTM) 74,81M
ROIC 19,32% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,14 Current Ratio 9,76
Interest Coverage 0,00 Dividend Yield 0,00%
Valuation
P/E Ratio 45,14 P/B Ratio 11,97
P/S Ratio 14,08 PEG Ratio -0,13
EV/EBITDA 37,99 Dividend Yield 0,00%
Market Cap 2,36B Enterprise Value 2,19B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2024 FY2023 FY2022
Revenue 167,50M 0,0 0,0
Net Income 52,23M -100,42M -114,94M
EPS (Diluted) 0,08 -2,29 -2,63
Gross Profit 167,50M 0,0 0,0
Operating Income 57,59M -98,55M -111,03M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2024 FY2023 FY2022
Total Assets 240,54M 71,50M 149,96M
Total Liabilities 43,64M 61,45M 48,51M
Shareholders' Equity 196,90M 10,05M 101,44M
Total Debt 26,63M 49,62M 32,06M
Cash & Equivalents 196,81M 29,16M 99,92M
Current Assets 201,67M 34,11M 106,15M
Current Liabilities 20,67M 16,32M 20,78M